Erste Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $169K | Hold |
33,500
| – | – | ﹤0.01% | 778 |
|
|
2025
Q1 | $195K | Hold |
33,500
| – | – | ﹤0.01% | 472 |
|
|
2024
Q4 | $248K | Hold |
33,500
| – | – | ﹤0.01% | 479 |
|
|
2024
Q3 | $234K | Hold |
33,500
| – | – | ﹤0.01% | 476 |
|
|
2024
Q2 | $254K | Hold |
33,500
| – | – | ﹤0.01% | 464 |
|
|
2024
Q1 | $341K | Hold |
33,500
| – | – | ﹤0.01% | 453 |
|
|
2023
Q4 | $355K | Hold |
33,500
| – | – | 0.01% | 450 |
|
|
2023
Q3 | $260K | Hold |
33,500
| – | – | ﹤0.01% | 464 |
|
|
2023
Q2 | $247K | Hold |
33,500
| – | – | ﹤0.01% | 474 |
|
|
2023
Q1 | $216K | Hold |
33,500
| – | – | ﹤0.01% | 484 |
|
|
2022
Q4 | $257K | Hold |
33,500
| – | – | 0.01% | 474 |
|
|
2022
Q3 | $360K | Hold |
33,500
| – | – | 0.01% | 454 |
|
|
2022
Q2 | $270K | Hold |
33,500
| – | – | 0.01% | 487 |
|
|
2022
Q1 | $239K | Buy |
+33,500
| New | +$239K | ﹤0.01% | 495 |
|